PSMA Scan Looks Superior to An Axumin Scan in Men with A Prostate  Cancer Recurrence

We should note that the two scans performed equally well in men who had their recurrence only in the prostate bed.  However, the trial also showed that the PSMA PET scan detected more cancerous pelvic lymph nodes and non-regional metastases.

Is Aloe Vera for Radiotherapy-Related Skin Reactions Effective?

Research shows that aloe vera alone is ineffective and may worsen skin reactions from radiation treatment. Research has shown that the cleansing the skin daily with mild moisturizing soaps is most beneficial. 

Germline Mutations As Prognostic Indicators of Castrate Resistance

In summary, these results demonstrate worse outcomes in men with germline BRCA2 and CHEK2 mutations compared with men without these mutations when treated with standard first-line ADT with LHRH analogs.

Evaluating PSMA-Targeted Radionuclide Therapy

This study did demonstrate that the level of PSMA expression of a man’s prostate cancer, the stronger the association with the likelihood of their having a PSA response. 

Is There A Role for Testosterone Therapy in the Treatment of Metastatic Prostate Cancer?

There has long been a discussion about the possible effects of using testosterone as a treatment for men with advanced metastatic prostate cancer.  In a poster presentation at ASCO 2019, it was shown that there are androgen receptor changes in the circulating-tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with high-dose testosterone. 

ADT With and Without Xtandi in Men with Metastatic Hormone Sensitive Prostate Cancer: The ARCHES Trial

After a median follow-up of 14.4 months, the men who had Xtandi along with ADT experienced an improved radiographic progression-free survival advantage over those who had only ADT, regardless of their prior treatment. 

Short Term ADT with Radiotherapy As Salvage Treatment After Surgery: Update at 9 years of the GETUG-AFU 16 phase III Randomized Trial 

Findings confirm the better strategy for salvage therapy after failed surgery for prostate cancer is ADT along with radiotherapy,

Darolutamide - Great Results From The ARAMIS Trial For Men With M0 Prostate Cancer

The ARAMIS Trial showed that darolutamide increased overall survival for men with prostate cancer, it delayed the time to the use of cytotoxic chemotherapy as well as improving the important quality of life (QoL) measures of time to pain progression, and time to developing a symptomatic skeletal-related event.  

The ENZAMET Study: Adding Enzalutamide to ADT in Metastatic Hormone-Sensitive Prostate Cancer Extends Survival

The trial found that 80% of men with metastatic hormone-sensitiveprostate cancer who received enzalutamide (Xtandi) along with standard-of-care treatment (ADT) were alive after three years, compared with just 72% of men who received other nonsteroidal antiandrogens along with standard ADT therapy.

An Important Update on the Use of Radium in Combination with Zytiga and Xtandi

Make sure that you and your doctor use the bone-protecting approved medications (zoledronic acid or denosumab), especially for at least three weeks before using Xofigo (Radium-223).

When to Start ADT With A PSA Only Recurrence

Deferred hormone therapy (ADT) for in relapsing M0 (negative scans) prostate cancer patients is associated with prolonged overall survival (OS) measured from the time of local treatment, comparable to OS with salvage ADT in the contemporary experience.

Reporting on Apalutamide (Erleada) for Castrate Sensitive Prostate Cancer

The use of apalutamide (Erleada) improved radiographic progression-free survival with a 52% reduction in risk of death or radiographic progression; that benefit was observed across all subgroups analyzed in the TITAN TRIAL for men with progressing prostate cancer that is still hormone sensitive. The median radiographic progression-free survival was not reached in the apalutamide group and was 22.1 months in the placebo group.